NEW YORK (GenomeWeb News) — Motif Biosciences has raised $1 million in series C financing to help pay for research into type 2 diabetes and asthma, partner company Amphion Innovations said today.
Amphion, which owns 47 percent of Motif, said it was responsible for $400,000 of the financing round.
in March, Motif reported receiving $1.8 million in financing, of which $500,000 came from Amphion.
Motif is a population-genetics company that focuses on links to diseases prevalent in populations in the Persian Gulf region.
Amphion said the lack of genetic diversity in this region make genomic and genetic analysis much easier.